Briacell Therap (NASDAQ:BCTX) vs. Polyrizon (NASDAQ:PLRZ) Financial Review

Briacell Therap (NASDAQ:BCTX) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Briacell Therap and Polyrizon, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1	0	1	0	2.00
Polyrizon	1	0	0	0	1.00

Briacell Therap presently has a consensus target price of $320.00, suggesting a potential upside of 7,307.41%. Given Briacell Therap’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Briacell Therap is more favorable than Polyrizon.

Earnings & Valuation

This table compares Briacell Therap and Polyrizon”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31 million	($23.33)	-0.19
Polyrizon	N/A	N/A	-$3.34 million	N/A	N/A

Profitability

This table compares Briacell Therap and Polyrizon’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-173.08%	-139.64%
Polyrizon	N/A	N/A	N/A

Volatility & Risk

Briacell Therap has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Polyrizon has a beta of -4.6, indicating that its share price is 560% less volatile than the S&P 500.

Insider and Institutional Ownership

15.4% of Briacell Therap shares are held by institutional investors. 0.7% of Briacell Therap shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Briacell Therap beats Polyrizon on 6 of the 9 factors compared between the two stocks.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

About Polyrizon

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.